Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression?
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The endocannabinoid (eCB) system, an endogenous lipid signaling system, appears to be dysregulated in depression. The role of endocannabinoids (eCBs) as potent immunomodulators, together with the accumulating support for a chronic low-grade inflammatory profile in depression, suggests a compelling hypothesis for a fundamental impairment in their intercommunication, in depression. OBJECTIVE: We aim to review previous literature on individual associations between the immune and eCB systems and depression. It will focus on peripheral and central mechanisms of crosstalk between the eCB and immune systems. A potential dysregulation in this crosstalk will be discussed in the context of depression. RESULTS: Investigations largely report a hypoactivity of the eCB system and increased inflammatory markers in individuals with depression. Findings depict a multifaceted communication whereby immunocompetent and eCB-related cells can both influence the suppression and enhancement of the other's activity in both the periphery and central nervous system. A dysregulation of the eCB system, as seen in depression, appears to be associated with central and peripheral concentrations of inflammatory agents implicated in the pathophysiology of this illness. CONCLUSION: The eCB and immune systems have been individually associated with and implicated in pathogenic mechanisms of depression. Both systems tightly regulate the other's activity. As such, a dysregulation in this crosstalk has potential to influence the onset and maintenance of this neuropsychiatric illness. However, few studies have investigated both systems and depression conjointly. This review highlights the demand to consider joint eCB-immune interactions in the pathoetiology of depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Structural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848 · cited 1×
“The influences of this chronic inflammatory state have been implicated in virtually every neuropathophysiologic abnormality associated with major depression (Miller et al. 2009).”
BackgroundA Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
Cytokines sing the blues: inflammation and the pathogenesis of depression
Raison, C. L., Capuron, L., & Miller, A. H. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.006 · Cited by 3,009 · cited 2×
“…for the resulting increase in CNS inflammation following peripheral inflammation, elevated inflammatory markers within the CNS are a common finding in the pathophysiology of depression (Levine et al. 1999; Raison et al. 2006, 2009; Howren et al. 2009; M iller et al.2009; Dowlati et al. 2010).”
BackgroundMechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 1×
“…components: (1) the endogenous lipid trans-mitters: endocannabinoids (eCBs) anandamide (AEA) and 2-arachidonoylglycerol (2-AG) (Devane et al. 1992; Mechoulam et al. 1995); (2) the target of these eCBs: G-protein-coupled receptors, cannabinoid receptor type 1 (CB1R) and 2 (CB2R) (Matsuda et al.…”
BackgroundAssociations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Immunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125 · cited 6×
“Immune cells are also involved in termination of eCB signalling through direct uptake and degradation of AEA and 2-eCB Alternatively, degradation of eCBs can occur via enzymes, either MAGL or FAAH, into AA, which is subsequently oxidised by COX and LOX to produce PGEs and leukotrienes, respectively.”
BackgroundInfluentialThe HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009
Self-citationHippocampal atrophy in recurrent major depression
Sheline, Y. I., Wang, P. W., Gado, M. H., Csernansky, J. G., & Vannier, M. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3908 · Cited by 1,932 · cited 1×
“Of relevance to depression is the aforementioned neural atrophy associated reductions in BDNF in the hippocampus, as this feature has been observed in major depression and associated animal models (Sheline et al. 1996; Santarelli et al. 2003; Lee and Kim 2010).”
BackgroundNeuroinflammation and M2 Microglia: The Good, the Bad, and the Inflamed
Cherry, J. D., Olschowka, J. A., & O’Banion, M. K. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-98 · Cited by 1,748 · cited 2×
“a classic activated state (M1) and the alternative state (M2) (Cherry et al. 2014).”
BackgroundWillner, P. (2005) · Neuropsychobiology · doi:10.1159/000087097 · Cited by 1,605 · cited 2×
“evokes a symptomatic profile similar to a human depressive phenotype (Willner 2005).”
BackgroundSo depression is an inflammatory disease, but where does the inflammation come from?
Berk, M., Williams, L. J., Jacka, F. N., O’Neil, A., Pasco, J. A., Moylan, S., Allen, N. B., Stuart, A. L., Hayley, A. C., Byrne, M. L., et al. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-200 · Cited by 1,423 · cited 1×
“Research has supported the involvement of immunedysregulation and more specifically, a low-grade inflammation, in depression (Berk et al. 2013).”
BackgroundTyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67763-x · Cited by 1,069 · cited 2×
“Interestingly, in a subsequent investigation, etanercept, a biopharmaceutical with antiinflammatory properties, significantly reduced the depressive symptomatology presented in the same patient group, independently of any improvements in the condition (Tyring et al. 2006).”
BackgroundMicroglia and neuroinflammation: a pathological perspective
Streit (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-14 · Cited by 1,039
Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., Matias, I., Schiano-Moriello, A., Paul, P., Williams, E.-J., et al. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200305129 · Cited by 1,039 · cited 3×
“…enzymes involved in the synthesis, namely N -acylphosphatidylethanolamine-hydolyzing phospholipase D (NAPE-PLD) and diacylglycerol lipase (DAGL) (Bisogno et al. 2003; Okamoto et al. 2004) and degradation enzymes including fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)…”
BackgroundThe Relationship of Depression and Stressors to Immunological Assays: A Meta-Analytic Review
Zorrilla, E. P., Luborsky, L., McKay, J. R., Rosenthal, R., Houldin, A., Tax, A., McCorkle, R., Seligman, D. A., & Schmidt, K. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0597 · Cited by 995 · cited 1×
“Surprisingly, the opposite is largely described in the literature, with reports of reduced T cell concentration in peripheral bloods of depressed patients compared to controls (Maes et al. 1995b; Zorrilla et al. 2001; Irwin and Miller 2007).”
ResultKöhler, O., Benros, M. E., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1611 · Cited by 941
Steiner, J., Bielau, H., Brisch, R., Danos, P., Ullrich, O., Mawrin, C., Bernstein, H.-G., & Bogerts, B. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.10.013 · Cited by 791
Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation
Nomura, D. K., Morrison, B. E., Blankman, J. L., Long, J. Z., Kinsey, S. G., Marcondes, M. C. G., Ward, A. M., Hahn, Y. K., Lichtman, A. H., Conti, B., et al. (2011) · Science · doi:10.1126/science.1209200 · Cited by 727
Depressive disorders and immunity: 20 years of progress and discovery
Irwin, M. R., & Miller, A. H. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2007.01.010 · Cited by 676
Kreisel, T., Frank, M. G., Licht, T., Reshef, R., Ben-Menachem-Zidon, O., Baratta, M. V., Maier, S. F., & Yirmiya, R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.155 · Cited by 663 · cited 1×
“…models of depression delineate altered expression of microglial activation markers, as well as chronicity-dependent fluctuations in microglial concentration in areas of the brain associated with mood regulation (Hinwood et al. 2012; Wohleb et al. 2012; Couch et al. 2013; Kreisel et al. 2014).”
BackgroundHirvonen, J., Goodwin, R. S., Li, C.-T., Terry, G. E., Zoghbi, S. S., Morse, C., Pike, V. W., Volkow, N. D., Huestis, M. A., & Innis, R. B. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.82 · Cited by 587
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.
Burstein, S. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.059 · Cited by 573 · cited 2×
“tagonist administration reverses this immunosuppression (Hanus et al. 1999; Burstein 2015).”
BackgroundGlucocorticoids, cytokines and brain abnormalities in depression
Zunszain, P. A., Anacker, C., Cattaneo, A., Carvalho, L. A., & Pariante, C. M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.04.011 · Cited by 554
Self-citationJiang, W. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25509 · Cited by 527
Patel, S., Roelke, C. T., Rademacher, D. J., Cullinan, W. E., & Hillard, C. J. (2004) · Endocrinology · doi:10.1210/en.2004-0638 · Cited by 475 · cited 1×
“Pharmacological blockade of the CB1Rs disrupts this tonic regulation and results in increased corticosterone levels (Patel et al. 2004; Wade et al. 2006).”
BackgroundSpecialized pro-resolving lipid mediators in the inflammatory response: An update
Bannenberg, G., & Serhan, C. N. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.08.002 · Cited by 464 · cited 2×
“Increased concentrations of LXA 4 are associated with the resolution phase of an acute inflammatory response, in which it induces inflammatory cell apoptosis (Bannenberg and Serhan 2010).”
BackgroundImmune mechanisms linked to depression via oxidative stress and neuroprogression
Bakunina, N., Pariante, C. M., & Zunszain, P. A. (2015) · Immunology · doi:10.1111/imm.12443 · Cited by 444 · cited 1×
“Such unabated inflammation results in several molecular cascades associated with alterations in neurotransmitter metabolism and neuroendocrine function typically present in depression (Bakunina et al. 2015).”
BackgroundSelf-citationCattaneo, A., Gennarelli, M., Uher, R., Breen, G., Farmer, A., Aitchison, K. J., Craig, I. W., Anacker, C., Zunsztain, P. A., McGuffin, P., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.191 · Cited by 436
Self-citationHinwood, M., Morandini, J., Day, T. A., & Walker, F. R. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhr229 · Cited by 420
Neurobiology of chronic mild stress: parallels to major depression
Hill, M. N., Hellemans, K. G. C., Verma, P., Gorzalka, B. B., & Weinberg, J. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.07.001 · Cited by 420 · cited 1×
“Through tonic regulation of the HPA-axis, eCB activity, mediated via CB1Rs, is responsible for maintaining basal tone (Hill and Tasker 2012b).”
BackgroundRiazi, K., Galic, M. A., Kuzmiski, J. B., Ho, W., Sharkey, K. A., & Pittman, Q. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806682105 · Cited by 400
The current state of the neurogenic theory of depression and anxiety
Miller, B. R., & Hen, R. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.08.012 · Cited by 386
Raison, C. L., Borisov, A. S., Majer, M., Drake, D. F., Pagnoni, G., Woolwine, B. J., Vogt, G. J., Massung, B., & Miller, A. H. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.010 · Cited by 367 · cited 1×
“…for the resulting increase in CNS inflammation following peripheral inflammation, elevated inflammatory markers within the CNS are a common finding in the pathophysiology of depression (Levine et al. 1999; Raison et al. 2006, 2009; Howren et al. 2009; M iller et al.2009; Dowlati et al. 2010).”
BackgroundThe monocyte-T-lymphocyte hypothesis of major depression
Maes, M., Smith, R., & Simon, S. (1995) · Psychoneuroendocrinology · doi:10.1016/0306-4530(94)00066-j · Cited by 299
Bahi, A., Al Mansouri, S., Al Memari, E., Al Ameri, M., Nurulain, S. M., & Ojha, S. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.06.003 · Cited by 291
Wohleb, E. S., Fenn, A. M., Pacenta, A. M., Powell, N. D., Sheridan, J. F., & Godbout, J. P. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.02.003 · Cited by 275
Zhang, T., Pang, C., Li, N., Zhou, E., & Zhao, K. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-1 · Cited by 270
Topol, E. J., Bousser, M.-G., Fox, K. A., Creager, M. A., Despres, J.-P., Easton, J. D., Hamm, C. W., Montalescot, G., Steg, P. G., Pearson, T. A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60935-x · Cited by 266
Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects
Onaivi, E. S., Ishiguro, H., Gong, J.-P., Patel, S., Meozzi, P. A., Myers, L., Perchuk, A., Mora, Z., Tagliaferro, P. A., Gardner, E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001640 · Cited by 257
Hill, M. N., Carrier, E. J., McLaughlin, R. J., Morrish, A. C., Meier, S. E., Hillard, C. J., & Gorzalka, B. B. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05567.x · Cited by 246 · cited 3×
“Reduced eCB signalling is further supported by a significant decrease in levels of AEA in regions associated with behaviour, such as the hippocampus, hypothalamus, amygdala and ventral striatum (Hill et al. 2008a).”
BackgroundCencioni, M. T., Chiurchiù, V., Catanzaro, G., Borsellino, G., Bernardi, G., Battistini, L., & Maccarrone, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008688 · Cited by 235 · cited 2×
“For example, AEA suppresses human T lymphocyte proliferation and this is dependent on CB2R action, as shown by replication of the afore-mentioned effect by administration of CB2R agonist and amelioration following use of a CB2R antagonist (Cencioni et al. 2010).”
BackgroundSong, C., Lin, A., Bonaccorso, S., Heide, C., Verkerk, R., Kenis, G., Bosmans, E., Scharpe, S., Whelan, A., Cosyns, P., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00025-1 · Cited by 232 · cited 1×
“Elevated levels of PGE 2 in plasma, serum and saliva have been measured in patients with MDD (Lieb et al. 1983; Ohishi et al. 1988; Song et al. 1998).”
BackgroundMendlewicz, J., Kriwin, P., Oswald, P., Souery, D., Alboni, S., & Brunello, N. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200607000-00005 · Cited by 229
Hannestad, J., DellaGioia, N., Gallezot, J.-D., Lim, K., Nabulsi, N., Esterlis, I., Pittman, B., Lee, J.-Y., O’Connor, K. C., Pelletier, D., et al. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.06.010 · Cited by 204
Depression‐resistant endophenotype in mice overexpressing cannabinoid CB 2 receptors
García‐Gutiérrez, M., Pérez‐Ortiz, J., Gutiérrez‐Adán, A., & Manzanares, J. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00819.x · Cited by 196
Couch, Y., Anthony, D. C., Dolgov, O., Revischin, A., Festoff, B., Santos, A. I., Steinbusch, H. W., & Strekalova, T. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.12.017 · Cited by 187 · cited 1×
“…models of depression delineate altered expression of microglial activation markers, as well as chronicity-dependent fluctuations in microglial concentration in areas of the brain associated with mood regulation (Hinwood et al. 2012; Wohleb et al. 2012; Couch et al. 2013; Kreisel et al. 2014).”
BackgroundDepression-like phenotype following chronic CB1 receptor antagonism
Beyer, C. E., Dwyer, J. M., Piesla, M. J., Platt, B. J., Shen, R., Rahman, Z., Chan, K., Manners, M. T., Samad, T. A., Kennedy, J. D., et al. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.03.020 · Cited by 160 · cited 3×
“Pharmacological blockade of CB1R suppressed dentate gyrus progenitor proliferation and reduced brain derived neurotrophic factor (BDNF) content in the hippocampus (Lee et al. 2009; Beyer et al. 2010).”
BackgroundResultBarna, I., Zelena, D., Arszovszki, A. C., & Ledent, C. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.06.006 · Cited by 136 · cited 2×
“Likewise, CB1R KO mice exhibited depressive-like symptoms and a concomitantly higher basal adrenocorticotropicreleasing hormone level, in comparison to wild-type mice (Barna et al. 2004).”
ResultMcLaughlin, R. J., Hill, M. N., Dang, S. S., Wainwright, S. R., Galea, L. A. M., Hillard, C. J., & Gorzalka, B. B. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.09.053 · Cited by 65 · cited 2×
“This increase however is suggested to be a compensatory effect of reduced eCB signalling as demonstrated by studies that reported decreased PFC AEA content (Hill et al. 2008a) and exacerbated depression following CB1R antagonist administration (McLauglin et al. 2013).”
Background
Cited by
Guida, F., Turco, F., Iannotta, M., De Gregorio, D., Palumbo, I., Sarnelli, G., Furiano, A., Napolitano, F., Boccella, S., Luongo, L., et al. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.09.001 · Cited by 367
The endocannabinoid system as a target for novel anxiolytic drugs
Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.033 · Cited by 233
al'Absi, M., & Allen, A. M. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.687106 · Cited by 34
“…there is evidence that disruption of the eCB system is associated with poor adaptation to stress and that a deficient eCB system is implicated in psychopathology and emotional disorders (Parolaro et al., 2010; Marco and Laviola, 2012; Tan et al., 2014; Boorman et al., 2016; Ney et al., 2018).”
BackgroundIs cannabis a risk factor for suicide attempts in men and women with psychotic illness?
Waterreus, A., Di Prinzio, P., Badcock, J. C., Martin-Iverson, M., Jablensky, A., & Morgan, V. A. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4924-6 · Cited by 23
Kalkman, H. O. (2023) · Biomedicines · doi:10.3390/biomedicines11030806 · Cited by 18
Metadata
- Authors
- Boorman, E., Zajkowska, Z., Ahmed, R., Pariante, C. M., & Zunszain, P. A.
- Venue
- Psychopharmacology
- Published
- 2015-10-20
- Volume
- 233
- Issue
- 9
- Pages
- 1591-1604
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W1811422264
- Cited by
- 66
- References
- 52
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.